Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
Treace Medical Concepts (NasdaqGS: TMCI), a medical technology company specializing in surgical treatments for bunions and midfoot deformities through its Lapiplasty® and Adductoplasty® Procedures, has announced it will release its fourth quarter and full-year 2024 financial results after market close on February 27, 2025.
The company will host a conference call with management at 4:30 pm ET on the same day to discuss the results. Interested investors can register to receive dial-in numbers and a unique pin to participate and ask questions. A live and archived webcast will be available on the company's investor relations website.
Treace Medical Concepts (NasdaqGS: TMCI), un'azienda di tecnologia medica specializzata in trattamenti chirurgici per alluce valgo e deformità del mesopiede tramite le sue procedure Lapiplasty® e Adductoplasty®, ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 dopo la chiusura del mercato il 27 febbraio 2025.
L'azienda ospiterà una conferenza telefonica con il management alle 16:30 ET dello stesso giorno per discutere i risultati. Gli investitori interessati possono registrarsi per ricevere i numeri di accesso e un pin unico per partecipare e porre domande. Sarà disponibile un webcast dal vivo e registrato sul sito web delle relazioni con gli investitori dell'azienda.
Treace Medical Concepts (NasdaqGS: TMCI), una empresa de tecnología médica especializada en tratamientos quirúrgicos para juanetes y deformidades del mediopié a través de sus procedimientos Lapiplasty® y Adductoplasty®, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 después del cierre del mercado el 27 de febrero de 2025.
La empresa llevará a cabo una conferencia telefónica con la gerencia a las 4:30 p. m. ET el mismo día para discutir los resultados. Los inversores interesados pueden registrarse para recibir los números de acceso y un pin único para participar y hacer preguntas. Habrá una transmisión en vivo y grabada disponible en el sitio web de relaciones con inversores de la empresa.
Treace Medical Concepts (NasdaqGS: TMCI)는 Lapiplasty® 및 Adductoplasty® 절차를 통해 무지외반증 및 중족골 변형에 대한 외과적 치료를 전문으로 하는 의료 기술 회사로, 2024년 4분기 및 연간 재무 결과를 2025년 2월 27일 시장 종료 후 발표할 것이라고 발표했습니다.
회사는 같은 날 오후 4시 30분 ET에 경영진과 함께 결과를 논의하는 전화 회의를 주최할 예정입니다. 관심 있는 투자자는 참여 및 질문을 하기 위해 접속 번호와 고유한 핀을 받기 위해 등록할 수 있습니다. 회사의 투자자 관계 웹사이트에서 라이브 및 보관된 웹캐스트가 제공됩니다.
Treace Medical Concepts (NasdaqGS: TMCI), une entreprise de technologie médicale spécialisée dans les traitements chirurgicaux pour les oignons et les déformations du médio-pied grâce à ses procédures Lapiplasty® et Adductoplasty®, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année entière 2024 après la fermeture du marché le 27 février 2025.
L'entreprise organisera une conférence téléphonique avec la direction à 16h30 ET le même jour pour discuter des résultats. Les investisseurs intéressés peuvent s'inscrire pour recevoir les numéros d'appel et un code PIN unique pour participer et poser des questions. Un webcast en direct et enregistré sera disponible sur le site web des relations investisseurs de l'entreprise.
Treace Medical Concepts (NasdaqGS: TMCI), ein Medizintechnikunternehmen, das sich auf chirurgische Behandlungen von Hallux Valgus und Mittelfußdeformitäten mit seinen Verfahren Lapiplasty® und Adductoplasty® spezialisiert hat, hat bekannt gegeben, dass es seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 nach Marktschluss am 27. Februar 2025 veröffentlichen wird.
Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz mit dem Management abhalten, um die Ergebnisse zu besprechen. Interessierte Investoren können sich registrieren, um Zugangsnummern und eine eindeutige PIN zu erhalten, um an der Konferenz teilzunehmen und Fragen zu stellen. Ein Live- und Archiv-Webcast wird auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
PONTE VEDRA, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Thursday, February 27, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.
Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net
FAQ
When will Treace Medical Concepts (TMCI) release Q4 and full-year 2024 earnings?
How can investors join TMCI's Q4 2024 earnings call?
What time is Treace Medical Concepts' (TMCI) Q4 2024 earnings call?
Where can I find TMCI's Q4 2024 earnings webcast?
